Bafna Pharmaceuticals Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 5/6

Bafna Pharmaceuticals hat ein Gesamteigenkapital von ₹808.4M und eine Gesamtverschuldung von ₹243.9M, wodurch sich der Verschuldungsgrad auf 30.2% beläuft. Die Gesamtaktiva und Gesamtpassiva betragen ₹1.5B bzw. ₹668.4M. Bafna Pharmaceuticals Das EBIT des Unternehmens beträgt ₹61.2M, so dass der Zinsdeckungsgrad 2.7 beträgt. Das Unternehmen verfügt über Barmittel und kurzfristige Anlagen in Höhe von ₹14.0M.

Wichtige Informationen

30.2%

Verhältnis von Schulden zu Eigenkapital

₹243.89m

Verschuldung

Zinsdeckungsgrad	2.7x
Bargeld	₹13.96m
Eigenkapital	₹808.39m
Gesamtverbindlichkeiten	₹668.43m
Gesamtvermögen	₹1.48b

Jüngste Berichte zur Finanzlage

We Think Bafna Pharmaceuticals (NSE:BAFNAPH) Can Stay On Top Of Its Debt

Aug 15

Recent updates

We Think Bafna Pharmaceuticals (NSE:BAFNAPH) Can Stay On Top Of Its Debt

Aug 15

Optimistic Investors Push Bafna Pharmaceuticals Limited (NSE:BAFNAPH) Shares Up 27% But Growth Is Lacking

Feb 13

The Strong Earnings Posted By Bafna Pharmaceuticals (NSE:BAFNAPH) Are A Good Indication Of The Strength Of The Business

Nov 19

Do Its Financials Have Any Role To Play In Driving Bafna Pharmaceuticals Limited's (NSE:BAFNAPH) Stock Up Recently?

Dec 10

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: BAFNAPHDie kurzfristigen Aktiva des Unternehmens (₹909.5M) übersteigen seine kurzfristigen Passiva (₹442.2M).

Langfristige Verbindlichkeiten: BAFNAPHDie kurzfristigen Vermögenswerte des Unternehmens (₹909.5M) übersteigen seine langfristigen Verbindlichkeiten (₹82.8M).

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: BAFNAPHDie Nettoverschuldung im Verhältnis zum Eigenkapital (10.6%) wird als zufriedenstellend angesehen.

Schulden abbauen: BAFNAPH Das Verhältnis von Schulden zu Eigenkapital ist in den letzten 5 Jahren von 198.1% auf 20.1% zurückgegangen.

Schuldendeckung: BAFNAPHDie Schulden des Unternehmens sind gut durch den operativen Cashflow gedeckt (93.5%).

Zinsdeckung: BAFNAPHDie Zinszahlungen für die Schulden des Unternehmens sind durch das EBIT (2.7x Deckung) nicht gut gedeckt.

Bafna Pharmaceuticals Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 5/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

We Think Bafna Pharmaceuticals (NSE:BAFNAPH) Can Stay On Top Of Its Debt

Recent updates

Bafna Pharmaceuticals Limited Approves the Appointment of A. Mohanachandran as Company Secretary and Compliance Officer

Bafna Pharmaceuticals Limited to Report Q4, 2024 Results on May 29, 2024

Investor sentiment improves as stock rises 21%

Investor sentiment improves as stock rises 17%

Bafna Pharmaceuticals Limited to Report Q3, 2024 Results on Feb 12, 2024

Second quarter 2024 earnings released: EPS: ₹1.05 (vs ₹0.68 in 2Q 2023)

Bafna Pharmaceuticals Limited to Report Q2, 2024 Results on Nov 09, 2023

Investor sentiment improves as stock rises 15%

Bafna Pharmaceuticals Limited Announces Resignation of Kamlesh Kumar Babulal as Non-Executive Independent Director from the Board

First quarter 2024 earnings released: EPS: ₹2.68 (vs ₹0.57 in 1Q 2023)

Investor sentiment improves as stock rises 16%

We Think Bafna Pharmaceuticals (NSE:BAFNAPH) Can Stay On Top Of Its Debt

Bafna Pharmaceuticals Limited, Annual General Meeting, Sep 22, 2023

Bafna Pharmaceuticals Limited to Report Q1, 2024 Results on Aug 11, 2023

High number of new directors

Investor sentiment improves as stock rises 27%

Full year 2023 earnings released: EPS: ₹4.86 (vs ₹2.17 in FY 2022)

Bafna Pharmaceuticals Limited to Report Q4, 2023 Results on May 24, 2023

Third quarter 2023 earnings released: EPS: ₹1.26 (vs ₹0.72 in 3Q 2022)

Bafna Pharmaceuticals Limited to Report Q3, 2023 Results on Feb 08, 2023

Bafna Pharmaceuticals Limited Announces Resignation of Atul Sachdeva as Director

Second quarter 2023 earnings released: EPS: ₹0.68 (vs ₹0.95 in 2Q 2022)

High number of new and inexperienced directors

Second quarter 2023 earnings released: EPS: ₹0.68 (vs ₹0.95 in 2Q 2022)

Bafna Pharmaceuticals Limited Announces Resignation of Roopa Ravikumar as Company Secretary and Compliance Officer

First quarter 2023 earnings released: EPS: ₹0.57 (vs ₹0.88 in 1Q 2022)

Bafna Pharmaceuticals Limited, Annual General Meeting, Jul 28, 2022

Full year 2022 earnings released: EPS: ₹2.17 (vs ₹2.46 in FY 2021)

Full year 2022 earnings released: EPS: ₹2.17 (vs ₹2.46 in FY 2021)

Bafna Pharmaceuticals Limited to Report Q4, 2022 Results on May 26, 2022

High number of new and inexperienced directors

Investor sentiment improved over the past week

Optimistic Investors Push Bafna Pharmaceuticals Limited (NSE:BAFNAPH) Shares Up 27% But Growth Is Lacking

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Bafna Pharmaceuticals Limited to Report Q3, 2022 Results on Feb 10, 2022

Investor sentiment improved over the past week

Investor sentiment improved over the past week

The Strong Earnings Posted By Bafna Pharmaceuticals (NSE:BAFNAPH) Are A Good Indication Of The Strength Of The Business

Second quarter 2022 earnings released: EPS ₹0.95 (vs ₹0.20 in 2Q 2021)

Investor sentiment improved over the past week

Full year 2021 earnings released: EPS ₹2.46 (vs ₹9.17 loss in FY 2020)

Bafna Pharmaceuticals Limited to Report Q3, 2021 Results on Feb 12, 2021

New 90-day low: ₹123

New 90-day high: ₹202

Do Its Financials Have Any Role To Play In Driving Bafna Pharmaceuticals Limited's (NSE:BAFNAPH) Stock Up Recently?

Market pulls back on stock over the past week

Bafna Pharmaceuticals Limited Announces Board Changes

New 90-day high: ₹58.50

Bafna Pharmaceuticals Limited Announces CEO Appointment

Bafna Pharmaceuticals Limited to Report Q1, 2021 Results on Sep 10, 2020

Analyse der Finanzlage

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Bilanz

Entdecken Sie finanziell stabile Unternehmen